SIGA Technologies (SIGA) Q2 2026 profit falls as revenue drops to $41M
Rhea-AI Filing Summary
SIGA Technologies reported Q2 and first-half 2026 results, with continued TPOXX sales but lower revenue and profit versus 2025. For the three months ended June 30, 2026, total revenues were $41.0 million and net income $12.5 million, compared with $81.1 million and $35.5 million a year earlier; diluted EPS was $0.17.
The company delivered approximately $37 million of TPOXX in Q2, including $24 million of IV TPOXX to the U.S. strategic national stockpile and $13 million of oral TPOXX to two international customers. As of June 30, 2026, cash and cash equivalents were $117,584,444, total assets $175,736,786, and stockholders’ equity $165,290,635.
Positive
- None.
Negative
- Quarterly financial performance weakened year over year, with Q2 total revenues declining from $81.1 million to $41.0 million and net income from $35.5 million to $12.5 million, reflecting lower product sales compared with 2025.
Filing Explained
The furnished release adds exact first-half results and reports 71,844,042 common shares outstanding at June 30, 2026.
Form 8-K reports specified material events; this August 6 filing furnishes SIGA Technologies’ results for the quarter and six months ended
For the six months ended
The share count was
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenues Q2 2026: $41,002,253
Net income Q2 2026: $12,463,434
Diluted EPS Q2 2026: $0.17
+4 more
7 metrics
Total revenues Q2 2026
$41,002,253
Three months ended June 30, 2026
Net income Q2 2026
$12,463,434
Three months ended June 30, 2026
Diluted EPS Q2 2026
$0.17
Three months ended June 30, 2026
Product sales and supportive services Q2 2026
$37,870,335
Three months ended June 30, 2026
Cash and cash equivalents
$117,584,444
As of June 30, 2026
Total assets
$175,736,786
As of June 30, 2026
Total stockholders’ equity
$165,290,635
As of June 30, 2026
Key Terms
strategic national stockpile, deferred tax asset, accumulated deficit, BARDA Contract, +1 more
5 terms
strategic national stockpile regulatory
"IV TPOXX to the U.S. strategic national stockpile and $13 million"
A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.
deferred tax asset financial
"Deferred tax asset, net | | $ | 2,789,666 | | | | 4,428,519"
A deferred tax asset is an accounting recognition that a company expects to pay less tax in the future because of past losses or timing differences between accounting and tax rules; think of it as an IOU from the tax system that can reduce future tax bills. It matters to investors because it can boost future cash flow and reported profits if the company generates enough taxable income to use it, but its value depends on realistic prospects for future earnings.
accumulated deficit financial
"Accumulated deficit | | | (77,978,958 | ) | | | (43,070,803"
Accumulated deficit is the running total of a company’s past net losses minus any profits, showing how much the business has eaten into its own funds over time—think of it like a bank account that’s been overdrawn by repeated shortfalls. It matters to investors because a large accumulated deficit reduces the cushion that protects owners and creditors, can limit dividends or borrowing, and signals how much funding the company may need to reach profitability.
BARDA Contract regulatory
"performance under the 19C BARDA Contract (the "BARDA Contract"), with the U.S."
A BARDA contract is an award from the U.S. government agency that pays to develop, test or buy vaccines, diagnostics, treatments, or other public-health countermeasures. For investors it acts like a combination of grant and pre-order: it provides non-dilutive funding (no new shares required), milestone payments and possible future purchase commitments, which lower technical and market risk and can speed revenue and valuation growth.
biodefense market market
"the nascent international biodefense market does not develop to a degree"
Earnings Snapshot
Total revenues Q2 2026: $41,002,253
Three and six months ended June 30, 2026
Total revenues Q2 2026
$41,002,253
decreased from $81,120,004 in Q2 2025
Net income Q2 2026
$12,463,434
decreased from $35,483,103 in Q2 2025
Diluted EPS Q2 2026
$0.17
decreased from $0.49 in Q2 2025
Total revenues H1 2026
$47,244,834
decreased from $88,160,818 in H1 2025
Net income H1 2026
$9,009,184
decreased from $35,074,880 in H1 2025
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were SIGA (SIGA) total revenues for Q2 2026?
SIGA reported Q2 2026 total revenues of $41,002,253, compared with $81,120,004 in Q2 2025. Revenues include product sales, supportive services, and research and development income related to its TPOXX smallpox antiviral franchise.
How profitable was SIGA (SIGA) in the second quarter of 2026?
For Q2 2026, SIGA generated net and comprehensive income of $12,463,434, down from $35,483,103 a year earlier. Diluted income per share was $0.17 versus $0.49 in Q2 2025, reflecting lower sales volumes and reduced operating income.
How did SIGA (SIGA) product sales perform in the first half of 2026?
Product sales and supportive services totaled $41,408,212 for the six months ended June 30, 2026, versus $84,946,107 in the prior-year period. In Q2 alone, SIGA delivered about $37 million of TPOXX to three customers across U.S. and international markets.
What was SIGA (SIGA)'s cash position as of June 30, 2026?
As of June 30, 2026, SIGA held $117,584,444 in cash and cash equivalents, down from $154,966,414 at December 31, 2025. Total current assets were $170,377,782, and total assets were $175,736,786, supporting ongoing operations and contracts.
What were SIGA (SIGA)'s operating expenses in Q2 2026?
Total operating expenses for Q2 2026 were $27,096,675, versus $35,440,135 in Q2 2025. This included cost of sales and supportive services of $17,561,185, selling, general and administrative expenses of $5,148,992, and research and development expenses of $4,386,498.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer identification no.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
Registrant’s telephone number, including area code: (212 )
672-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On August 6, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial
results for the quarter ended June 30, 2026.
Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the
Press Release, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
The full text of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) The following exhibits are included in this report:
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Earning Press Release issued on August 6, 2026.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
SIGA TECHNOLOGIES, INC.
|
||
|
By:
|
/s/ Daniel J. Luckshire
|
|
|
Name:
|
Daniel J. Luckshire
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Date: August 6, 2026
|
||
Exhibit 99.1
 |
 |
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
| • |
$37 Million of TPOXX Sales Generated in the Second Quarter
|
| • |
Corporate Update Conference Call Today at 4:30 PM ET
|
NEW YORK, August 6, 2026 (GLOBENEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a
commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2026.
“In the second quarter, we delivered approximately $37 million of TPOXX to three customers: $24 million of IV TPOXX to the U.S. strategic national
stockpile and $13 million of oral TPOXX to two international customers,” stated Diem Nguyen, Chief Executive Officer. “With product deliveries across the U.S., Europe, and the Asia- Pacific region, spanning multiple formulations, SIGA continues to
execute its long-term plan of selling TPOXX across a diverse range of regions and customers.”
Summary Financial Results
|
($ in millions, except
per share amounts)
|
Three Months
Ended June 30
|
Six Months
Ended June 30
|
||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Product sales (1)
|
$
|
37.9
|
$
|
79.1
|
$
|
41.4
|
$
|
84.9
|
||||||||
|
Total revenues (2)
|
$
|
41.0
|
$
|
81.1
|
$
|
47.2
|
$
|
88.2
|
||||||||
|
Operating income(3) (4)
|
$
|
13.9
|
$
|
45.7
|
$
|
8.6
|
$
|
43.4
|
||||||||
|
Income before income taxes(3)
|
$
|
14.9
|
$
|
47.3
|
$
|
10.8
|
$
|
46.7
|
||||||||
|
Net income
|
$
|
12.5
|
$
|
35.5
|
$
|
9.0
|
$
|
35.1
|
||||||||
|
Diluted income per share
|
$
|
0.17
|
$
|
0.49
|
$
|
0.13
|
$
|
0.49
|
||||||||
|
(1)
|
Includes supportive services related to product sales.
|
|
(2)
|
Includes research and development revenues.
|
|
(3)
|
Operating income excludes, and income before income taxes includes, other income. Both line items exclude the
impact of income taxes.
|
|
(4)
|
Differences in operating income margin between periods reflect different product mixes in those periods.
|
|
|
Key Business and Operational Activity:
| • |
In the second quarter of 2026, the Company delivered approximately $13 million of oral TPOXX to two international customers.
|
| • |
In the second quarter of 2026, the Company delivered approximately $24 million of IV TPOXX to the U.S. strategic national stockpile under the 19C contract. These deliveries
completed the last procurement order under the 19C contract.
|
Capital Management Activity
| ■ |
On March 26, 2026, a special cash dividend of $0.60 per share was declared, and was paid on April 23, 2026, to shareholders of record at the close of
business on April 7, 2026.
|
Conference Call and Webcast
SIGA will host a conference call and webcast to provide a business update today, Thursday, August 6,
2026, at 4:30 P.M. ET.
Participants may access the call by dialing 1-800-717-1738 for
domestic callers or 1-646-307-1865 for international callers. A live webcast of the call will also be available on the Company's website at www.siga.com in the Investor Relations section of the website. Please log in approximately 5-10 minutes prior to the scheduled start time.
A replay of the call will be available for
two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 11157253. The archived webcast will be available in the Investor Relations section of the Company's website.
ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development
of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally,
or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit
www.siga.com.
|
|
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements relating to SIGA’s future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management
for future operations, and delivering products to domestic and international customers under procurement contracts. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,”
“should,” “target,” “goal,” “potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject
to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those
anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that SIGA is not able to secure in a timely manner new contracts with the U.S.
Government to substantially maintain or expand the U.S. Government stockpile of TPOXX®, (ii) the risk that SIGA may not complete performance under the 19C BARDA Contract (the "BARDA Contract"), with the U.S. Biomedical Advanced Research and
Development Authority ("BARDA") on schedule or in accordance with contractual terms, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX®
internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or
clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other
vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market
these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA’s patent and
other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or
additional testing or documentation that will delay or prevent SIGA from seeking, obtaining or maintaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper
SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xii) the effect of federal,
state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiii) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff measures,
and subsequent modifications or suspensions thereof, and market reactions to such policies and resulting trade disputes, (xiv) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and
development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xv) risks associated with actions or
uncertainties surrounding the debt ceiling, or the changes in the U.S. administration, and (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are
ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 and SIGA's subsequent filings with the Securities
and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were
made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Investor and Media Contact:
Suzanne Harnett
sharnett@siga.com
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
As of
|
|
June 30,
2026
|
December 31,
2025
|
||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
117,584,444
|
$
|
154,966,414
|
||||
|
Accounts receivable
|
7,170,229
|
3,263,736
|
||||||
|
Inventory
|
41,110,808
|
49,054,873
|
||||||
|
Prepaid expenses and other current assets
|
4,512,301
|
5,571,841
|
||||||
|
Total current assets
|
170,377,782
|
212,856,864
|
||||||
|
|
||||||||
|
Property, plant and equipment, net
|
1,530,954
|
1,090,824
|
||||||
|
Deferred tax asset, net
|
2,789,666
|
4,428,519
|
||||||
|
Goodwill
|
898,334
|
898,334
|
||||||
|
Other assets
|
140,050
|
192,893
|
||||||
|
Total assets
|
$
|
175,736,786
|
$
|
219,467,434
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
909,834
|
$
|
824,522
|
||||
|
Accrued expenses and other current liabilities
|
6,907,137
|
6,520,057
|
||||||
|
Deferred IV TPOXX® revenue
|
—
|
10,240,000
|
||||||
|
Income tax payable
|
28,335
|
408,000
|
||||||
|
Total current liabilities
|
7,845,306
|
17,992,579
|
||||||
|
|
||||||||
|
Other liabilities
|
2,600,845
|
2,653,283
|
||||||
|
Total liabilities
|
10,446,151
|
20,645,862
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,844,042 and 71,611,302, issued and outstanding at June 30, 2026 and
December 31, 2025, respectively)
|
7,184
|
7,161
|
||||||
|
Additional paid-in capital
|
243,262,409
|
241,885,214
|
||||||
|
Accumulated deficit
|
(77,978,958
|
)
|
(43,070,803
|
)
|
||||
|
Total stockholders’ equity
|
165,290,635
|
198,821,572
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
175,736,786
|
$
|
219,467,434
|
||||
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)
|
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
||||||||||||||
|
|
2026
|
2025
|
2026
|
2025
|
||||||||||||
|
Revenues
|
||||||||||||||||
|
Product sales and supportive services
|
$
|
37,870,335
|
$
|
79,124,860
|
$
|
41,408,212
|
$
|
84,946,107
|
||||||||
|
Research and development
|
3,131,918
|
1,995,144
|
5,836,622
|
3,214,711
|
||||||||||||
|
Total revenues
|
41,002,253
|
81,120,004
|
47,244,834
|
88,160,818
|
||||||||||||
|
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Cost of sales and supportive services
|
17,561,185
|
25,554,462
|
20,502,069
|
25,712,200
|
||||||||||||
|
Selling, general and administrative
|
5,148,992
|
5,487,576
|
9,822,005
|
11,163,238
|
||||||||||||
|
Research and development
|
4,386,498
|
4,398,097
|
8,336,344
|
7,860,910
|
||||||||||||
|
Total operating expenses
|
27,096,675
|
35,440,135
|
38,660,418
|
44,736,348
|
||||||||||||
|
Operating income
|
13,905,578
|
45,679,869
|
8,584,416
|
43,424,470
|
||||||||||||
|
Other income, net
|
946,898
|
1,592,304
|
2,224,378
|
3,277,288
|
||||||||||||
|
Income before income taxes
|
14,852,476
|
47,272,173
|
10,808,794
|
46,701,758
|
||||||||||||
|
Provision for income taxes
|
(2,389,042
|
)
|
(11,789,070
|
)
|
(1,799,610
|
)
|
(11,626,878
|
)
|
||||||||
|
Net and comprehensive income
|
$
|
12,463,434
|
$
|
35,483,103
|
$
|
9,009,184
|
$
|
35,074,880
|
||||||||
|
Basic income per share
|
$
|
0.17
|
$
|
0.50
|
$
|
0.13
|
$
|
0.49
|
||||||||
|
Diluted income per share
|
$
|
0.17
|
$
|
0.49
|
$
|
0.13
|
$
|
0.49
|
||||||||
|
Weighted average shares outstanding: basic
|
71,752,539
|
71,465,521
|
71,701,531
|
71,446,629
|
||||||||||||
|
Weighted average shares outstanding: diluted
|
71,883,798
|
71,748,888
|
71,998,573
|
71,678,838
|
||||||||||||